12 Month Price Forecast For GLSI
Distance to GLSI Price Forecasts
GLSI Price Momentum
🤔 Considering Greenwich LifeSciences (GLSI)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 23, 2025 7:36 AM UTC
GLSI Analyst Ratings & Price Targets
Based on our analysis of 2 Wall Street analysts, GLSI has a consensus that is bullish. The median price target is $38.00, with forecasts ranging from $38.00 to $38.00. Currently, there are 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With GLSI currently trading at $12.71, the median price forecast suggests a 199.0% upside. The most optimistic forecast comes from Yi Chen at HC Wainwright & Co., projecting a 199.0% upside, while Yi Chen at HC Wainwright & Co. provides the most conservative target, suggesting a 199.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GLSI Analyst Consensus
GLSI Price Target Range
Latest GLSI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GLSI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 23, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $38.00 |
| May 22, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $36.00 |
| Feb 28, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $36.00 |
| Feb 20, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $36.00 |
| Apr 10, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $38.00 |
| Sep 1, 2021 | HC Wainwright & Co. | Yi Chen | Buy | Initiates | $78.00 |
| Jan 27, 2021 | Aegis Capital | Buy | Initiates | $0.00 | |
| Jan 26, 2021 | Aegis Capital | Buy | Initiates | $0.00 |
Stocks Similar to Greenwich LifeSciences, Inc.
The following stocks are similar to Greenwich LifeSciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Greenwich LifeSciences, Inc. (GLSI) Financial Data
Greenwich LifeSciences, Inc. has a market capitalization of $167.59M with a P/E ratio of -18.4x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -123.7%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Greenwich LifeSciences, Inc. (GLSI) Company Overview
About Greenwich LifeSciences, Inc.
Develops cancer immunotherapies for breast cancer.
Greenwich LifeSciences operates as a clinical-stage biopharmaceutical company, focusing on developing innovative immunotherapies targeting breast cancer and other related cancers. The company's primary revenue potential lies in the successful commercialization of its lead product candidate, GP2, which is currently undergoing Phase III clinical trials aimed at preventing recurrence in breast cancer patients post-surgery.
Founded in 2006 and headquartered in Stafford, Texas, Greenwich LifeSciences was formerly known as Norwell, Inc. The name change occurred in March 2018, reflecting its focused commitment to cancer treatment solutions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
3
CEO
Mr. Snehal S. Patel
Country
United States
IPO Year
2020
Website
greenwichlifesciences.comGreenwich LifeSciences, Inc. (GLSI) Latest News & Analysis
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) is progressing with its Phase III trial, FLAMINGO-01, for GLSI-100, an immunotherapy aimed at preventing breast cancer recurrences.
Greenwich LifeSciences' update on its Phase III trial and GP2 manufacturing could signal advancements in breast cancer treatment, impacting stock performance and investor sentiment.
Glancy Prongay & Murray LLP Announces Investigation of Greenwich LifeSciences, Inc. (GLSI)
6 days agoGlancy Prongay & Murray LLP is investigating Greenwich LifeSciences, Inc. (NASDAQ: GLSI) for potential violations of state laws by the company and its executives. Investors may seek more information.
The investigation into Greenwich LifeSciences for potential legal violations could signal risks for shareholders, impacting stock performance and investor sentiment.
Greenwich LifeSciences (Nasdaq: GLSI) has started clinical sites in Germany for its Phase III trial, FLAMINGO-01, testing the immunotherapy GLSI-100 for preventing breast cancer recurrences.
Greenwich LifeSciences expanding its Phase III trial internationally may enhance its market potential, attract investment, and influence stock performance based on trial outcomes.
Greenwich LifeSciences (GLSI) is advancing its Phase III trial, FLAMINGO-01, for the immunotherapy GLSI-100, now partnering with clinical sites in Italy.
Greenwich LifeSciences' partnership with Italian clinical sites for its Phase III trial could enhance research credibility and accelerate drug development, impacting potential market value and investor confidence.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced updates on corporate events related to its immunotherapy GLSI-100 aimed at preventing breast cancer recurrences in post-surgery patients.
Greenwich LifeSciences' update on GLSI-100's development could impact its stock price, signaling progress or setbacks in a promising immunotherapy for breast cancer, influencing investor sentiment.
Greenwich LifeSciences (Nasdaq: GLSI) expanded its Phase III trial, FLAMINGO-01, for breast cancer immunotherapy GLSI-100 to include sites in Spain.
The expansion of clinical sites into Spain for Greenwich LifeSciences' trial may enhance data collection and market access, potentially increasing the stock's value and investor interest.
Frequently Asked Questions About GLSI Stock
What is Greenwich LifeSciences, Inc.'s (GLSI) stock forecast for 2025?
Based on our analysis of 2 Wall Street analysts, Greenwich LifeSciences, Inc. (GLSI) has a median price target of $38.00. The highest price target is $38.00 and the lowest is $38.00.
Is GLSI stock a good investment in 2025?
According to current analyst ratings, GLSI has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $12.71. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for GLSI stock?
Wall Street analysts predict GLSI stock could reach $38.00 in the next 12 months. This represents a 199.0% increase from the current price of $12.71. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Greenwich LifeSciences, Inc.'s business model?
Greenwich LifeSciences operates as a clinical-stage biopharmaceutical company, focusing on developing innovative immunotherapies targeting breast cancer and other related cancers. The company's primary revenue potential lies in the successful commercialization of its lead product candidate, GP2, which is currently undergoing Phase III clinical trials aimed at preventing recurrence in breast cancer patients post-surgery.
What is the highest forecasted price for GLSI Greenwich LifeSciences, Inc.?
The highest price target for GLSI is $38.00 from Yi Chen at HC Wainwright & Co., which represents a 199.0% increase from the current price of $12.71.
What is the lowest forecasted price for GLSI Greenwich LifeSciences, Inc.?
The lowest price target for GLSI is $38.00 from Yi Chen at HC Wainwright & Co., which represents a 199.0% increase from the current price of $12.71.
What is the overall GLSI consensus from analysts for Greenwich LifeSciences, Inc.?
The overall analyst consensus for GLSI is bullish. Out of 2 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $38.00.
How accurate are GLSI stock price projections?
Stock price projections, including those for Greenwich LifeSciences, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
